Erratum

View correction statement:

Erratum

This article refers to:

Erratum

In the Drug Evaluation by Harold S Minkowitz, titled ‘A review of sufentanil and the sufentanil sublingual tablet system for acute moderate to severe pain’, which appeared in the July 2015 issue of Pain Management 5(4), 237–250 (2015), the following footnote should be added to Table 7:

^§Scores are based on a 6-point scale (extremely dissatisfied to extremely satisfied).

Table 9 should also be presented as:

Table 9. Safety results of Phase III studies comparing sublingual sufentanil tablet system with intravenous patient-controlled analgesia with morphine sulfate or placebo system.

Safety parameter	Orthopedic^† and open abdominal surgeries [35]		Open abdominal surgery [36]		Orthopedic surgery^† [38]
	SSTS (n = 177)	iv. PCA MS (n = 180)	SSTS (n = 114)	Placebo (n = 58)	SSTS (n = 315)	Placebo (n = 104)
Possibly or probably related AEs occurring in ≥5% in any group, (%)
Nausea	43	40	14	22	35^*	22
Vomiting	13	11	4	3	11	6
Oxygen saturation decreased	10	9	4	2	7	3
Dizziness	6	3	3	2	5	1
Pruritus	4	8	4	0	5^*	0
Constipation	11	8	1	0	5	1
Headache	8	7	1	0	4	6
Hypotension	6	11	1	0	4	2

* p < 0.05.

† Total hip or total knee arthroplasty.

AE: Adverse event; iv. PCA MS: Intravenous patient-controlled analgesia with morphine sulfate; SSTS: Sublingual sufentanil tablet system.

The editors would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.